Loading
A phase 3 trial of Carboplatin in non-small-cell lung cancer and small-cell lung cancer, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.
A Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLC is a phase 3 interventional study registered as NCT04316364 by Jiangsu HengRui Medicine Co., Ltd., with 537 participants planned, started 2020-07-14 and due to reach its primary completion in 2023-04-15. Interventions recorded: SHR-1316、Paclitaxel (Albumin Bound)、Carboplatin, SHR-1316、Chemotherapeutic, Placebo、Chemotherapeutic. Conditions listed: Non-Small-Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Resectable stage I to III non-small-cell lung cancer, Small-cell lung cancer, Cytotoxic chemotherapy, Non-small-cell lung cancer.
Shares Jiangsu Hengrui Pharmaceuticals, Resectable stage I to III non-small-cell lung cancer, Carboplatin, Small-cell lung cancer.
Shares Resectable stage I to III non-small-cell lung cancer, Platinum agents, Carboplatin, Cytotoxic chemotherapy.
Shares Jiangsu Hengrui Pharmaceuticals, Carboplatin, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Resectable stage I to III non-small-cell lung cancer, Platinum agents, Carboplatin, Cytotoxic chemotherapy.
Shares Resectable stage I to III non-small-cell lung cancer, Carboplatin, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Resectable stage I to III non-small-cell lung cancer, Platinum agents, Carboplatin, Cytotoxic chemotherapy.
Shares Resectable stage I to III non-small-cell lung cancer, Carboplatin, Small-cell lung cancer, Non-small-cell lung cancer.